Top Page
Artrya Limited
(Sydney:AYA)
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Artrya Limited Business Overview & Revenue Model
Artrya Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.99M | -15.99M | -13.25M | -552.00K | -202.00K | -38.51K |
| EBITDA | -16.21M | -16.21M | -13.96M | -10.51M | -16.40M | -4.01M |
| Net Income | -16.41M | -16.41M | -14.00M | -11.14M | -17.16M | -4.08M |
Balance Sheet | ||||||
| Total Assets | 23.68M | 23.68M | 19.01M | 33.09M | 43.87M | 52.22M |
| Cash, Cash Equivalents and Short-Term Investments | 11.33M | 11.33M | 7.28M | 20.41M | 35.56M | 50.13M |
| Total Debt | 624.00K | 624.00K | 949.00K | 1.21M | 1.37M | 84.42K |
| Total Liabilities | 2.39M | 2.39M | 2.21M | 2.53M | 3.23M | 1.17M |
| Stockholders Equity | 21.29M | 21.29M | 16.80M | 30.56M | 40.64M | 51.05M |
Cash Flow | ||||||
| Free Cash Flow | -14.53M | -14.53M | -15.41M | -16.69M | -15.99M | -3.55M |
| Operating Cash Flow | -14.27M | -14.27M | -15.41M | -10.74M | -9.61M | -1.49M |
| Investing Cash Flow | -263.00K | 7.00K | 2.71M | 16.27M | -26.59M | -1.86M |
| Financing Cash Flow | 18.46M | 18.46M | -299.00K | -245.00K | 38.53M | 14.10M |
Artrya Limited Technical Analysis
Artrya Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$21.84M | -11.84 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$56.67M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
50 Neutral | AU$705.05M | -23.86 | -86.14% | ― | ― | 0.17% | |
44 Neutral | AU$10.57M | -1.03 | ― | ― | -40.05% | -49.57% | |
43 Neutral | AU$81.63M | -11.67 | ― | ― | ― | ― |
Artrya Limited Corporate Events
Artrya Limited has signed a five-year commercial software-as-a-service agreement with Cone Health, a major not-for-profit health system in North Carolina, marking the company’s third U.S. commercial customer for its Salix AI platform. Under the deal, Cone Health will deploy the Salix Coronary Anatomy module on a subscription basis across its network of hospitals and cardiology practices, with additional per-scan revenue for use of the Salix Coronary Plaque module, which is eligible for U.S. reimbursement, while onboarding and ongoing support will be handled by Artrya’s U.S.-based Customer Success team in Atlanta. The agreement, valued at a minimum of US$0.45 million over five years, completes the conversion of all three of Artrya’s U.S. foundation partners into paying customers in 2025, underscoring growing commercial momentum ahead of 2026 and strengthening the company’s foothold in the competitive U.S. cardiac imaging and diagnostics market.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced its first revenue generation from the Salix® Coronary Plaque module, following its integration into Tanner Health’s workflow in the U.S. This marks a significant milestone for Artrya as it expands its U.S. revenue opportunities through subscription and fee-per-scan models, supported by a U.S. Category 1 CPT reimbursement rate. The successful activation and integration of the module, facilitated by Artrya’s customer support team, is expected to enhance patient care and streamline operations at Tanner Health, potentially leading to broader adoption across their network.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has secured a three-year commercial agreement with Northeast Georgia Health System (NGHS), marking its second U.S. customer for the Salix® platform. The agreement, valued at a minimum of US$0.3 million, includes a SaaS license for the Salix® Coronary Anatomy platform and fee-per-scan revenue from the Salix® Coronary Plaque module, with potential expansion upon FDA clearance of the Salix® Coronary Flow module. This partnership is a significant step in Artrya’s U.S. expansion strategy, integrating its AI-powered platform into NGHS’s clinical workflow to enhance cardiovascular care and diagnostic precision. The rollout will be supported by Artrya’s Customer Success team in Atlanta, ensuring seamless integration and support for NGHS’s network of hospitals and the Georgia Heart Institute.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced that its Co-Founder and CEO, John Konstantopoulos, will present at the Bell Potter Healthcare Conference 2025. This virtual event, which brings together industry leaders and investors, will showcase Artrya’s advancements in AI-powered cardiac care solutions, potentially enhancing the company’s visibility and positioning in the healthcare industry.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced that its Co-Founder and CEO, John Konstantopoulos, will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. This event, which gathers industry leaders and investors, provides Artrya with an opportunity to showcase its AI-powered platform for coronary artery disease assessment, potentially enhancing its visibility and positioning in the medical technology sector.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced that all resolutions at its Annual General Meeting were passed, reflecting shareholder support for the company’s strategic direction. This development underscores Artrya’s commitment to leveraging its AI-powered platform for coronary artery disease management and reinforces its position in the medical technology industry.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced significant developments at its 2025 Annual General Meeting, highlighting FDA clearance for its Salix Coronary Anatomy and Plaque modules, and progress on the Coronary Flow module. The company is transitioning from research and development to a commercial phase, focusing on the U.S. market due to its size and growth potential. Artrya is establishing a base in Atlanta, Georgia, to support its U.S. operations and has raised $80 million to fund its path to profitability. The company’s unique point-of-care capability and lack of market penetration by competitors position it well for growth.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced the expansion of its SAPPHIRE Study to include Ascension, one of the largest non-profit health systems in the U.S. This inclusion marks the fourth major U.S. healthcare system to join the study, which aims to assess Artrya’s Salix® AI platform and Plaque Dispersion Score for early and effective detection of coronary artery disease. The study is set to commence in early 2026 and will focus on improving patient outcomes, particularly for women who often show no prior symptoms of coronary artery disease. Ascension’s participation is expected to enhance the study’s reach and impact, leveraging its extensive research capabilities and commitment to cardiovascular innovation.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced its upcoming Annual General Meeting (AGM) to be held on November 13, 2025, at its office in West Perth, Australia, with a webcast available for shareholders. This meeting is part of Artrya’s ongoing efforts to engage with stakeholders as it continues to commercialize its Salix AI-powered platform for coronary artery disease management, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced the application for quotation of 100,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code AYA. This move signifies a strategic step in enhancing the company’s capital structure, potentially impacting its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced the issuance of 100,000 ordinary shares following the exercise of vested employee performance rights. This move is part of the company’s efforts to enhance its operations and strengthen its position in the medical technology industry, particularly in the field of coronary artery disease management.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced that Mass General Brigham, a leading U.S. center for cardiac care, will participate in the SAPPHIRE Study, a retrospective multi-center trial set to begin in early 2026. This study aims to evaluate the clinical and prognostic value of Artrya’s Salix AI-powered platform in detecting coronary artery disease. The inclusion of Mass General Brigham, along with other high-volume U.S. cardiology sites, is expected to enhance Artrya’s presence in the U.S. market and support the company’s mission to improve early detection and management of heart disease.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced the quotation of 7,175,588 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 31, 2025. This move is part of a previously announced transaction, which may enhance the company’s liquidity and market presence, potentially benefiting stakeholders by increasing the company’s visibility and trading activity.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has completed Tranche 2 of its share placement, issuing 7,175,588 fully paid ordinary shares at $2.05 each, raising approximately $14.7 million. This capital injection is expected to bolster Artrya’s operations and enhance its market positioning as it continues to commercialize its AI-powered Salix platform for coronary artery disease management, potentially impacting stakeholders positively by advancing its technological and market goals.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has reported significant progress in its U.S. market expansion, highlighted by the successful integration with Tanner Health and the FDA clearance of its Salix® Coronary Plaque module. These milestones, along with a substantial capital raise of A$80M, position Artrya to accelerate its commercial operations and expand its customer base in the U.S. market. The company is also preparing for the SAPPHIRE study, which aims to advance coronary artery disease diagnostics, particularly focusing on women, and is set to commence in early 2026.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced that all resolutions presented at its General Meeting of Shareholders were passed. This development signifies strong shareholder support for the company’s strategic initiatives, including the ratification and approval of placement shares, which are likely to bolster Artrya’s financial position and support its expansion efforts in the medical technology sector.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced the quotation of 12,500 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code AYA, effective from October 23, 2025. This move is part of the company’s strategy to expand its capital base, potentially enhancing its market presence and operational capabilities in the healthcare technology sector.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited announced the issuance of 12,500 ordinary shares following the exercise of vested employee performance rights. This move reflects the company’s commitment to incentivizing its workforce as it continues to commercialize its Salix AI-powered platform for coronary artery disease management. The issuance of shares is a strategic step in enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting its market positioning and stakeholder value.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.